ZURICH, Aug 5 (Reuters) - Roche Holding said itsTecentriq drug combined with platinum-based chemotherapy reducedthe risk of the disease worsening or death in patients withadvanced bladder cancer, the Swiss pharma company said onMonday.
Tecentriq was the first cancer immunotherapy approved inbladder cancer, with Roche now evaluating the treatment incombination with other medicines for early and advanced forms ofthe disease.
The Phase III study met its targets of preventing thecondition worsening, when compared with chemotherapy alone.Roche said it would share the data with the U.S. Food and DrugAdministration and the European Medicines Agency.(Reporting by John Revill, editing by Riham Alkousaa)